Drug Profile
Research programme: hypertension therapeutics - Innovation Pharmaceuticals
Alternative Names: KM 732; KM-372Latest Information Update: 09 Jun 2017
Price :
$50
*
At a glance
- Originator Cellceutix
- Developer Innovation Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Hypertension
Most Recent Events
- 07 Jun 2017 Cellceutix is now called Innovation Pharmaceuticals
- 25 Aug 2009 Preclinical trials in Hypertension in USA (unspecified route)